HSP

Heat shock proteins

HSP (Heat shock proteins) are a group of proteins induced by heat shock, the most prominent members of this group are a class of functionally related proteins involved in the folding and unfolding of other proteins. HSP expression is increased when cells are exposed to elevated temperatures or other stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins appear to serve a significant cardiovascular role. Hsp90, Hsp84, Hsp70, Hsp27, Hsp20 and alpha B crystallin all have been reported as having roles in the cardiovasculature.

HSP Inhibitors, Antagonists & Activators

10,11-Dehydrocurvularin

Cat. No.: HY-N6679A

10,11-Dehydrocurvularin is a prevalent fungal phytotoxin and an antibiotic.
10,11-Dehydrocurvularin is a strong activator of the **heat shock response**. 10,11-Dehydrocurvularin inhibits **TGF-β signalling** pathway. Anti-tumorous activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

116-9e

(MAL2-11B)

Cat. No.: HY-116683

116-9e (MAL2-11B) is a **Hsp70 co-chaperone DNAJA1** inhibitor. 116-9e inhibits **Simian Virus 40 (SV40)** replication and **DNA synthesis**. 116-9e inhibits tumor antigen (TAg)'s endogenous ATPase activity and the TAg-mediated activation of Hsp70.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

17-AEP-GA

Cat. No.: HY-133570

17-AEP-GA, an **HSP90** antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. ADCs Toxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

17-GMB-APA-GA

Cat. No.: HY-130997

17-GMB-APA-GA is an **ADC Cytotoxin**. 17-GMB-APA-GA is a potent **HSP90** inhibitor and used for latent T. gondii infection research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Hexyl-4-pentynoic acid

((±)-2-Hexyl-4-pentynoic acid)

Cat. No.: HY-118783

2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of **HDAC** inhibition (IC_{50}=13 μM) and **HSP70** induction. Potent neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Phenyltoxoflavin

Cat. No.: HY-125759

3-Phenyltoxoflavin, a derivative of Toxoflavin, is an **Hsp90** inhibitor, with a K_d of 585 nM for the interaction of Hsp90-TPR2A. 3-Phenyltoxoflavin has anti-cancer activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

6BrCaQ

Cat. No.: HY-144830

6BrCaQ is a potent **mitochondrial heat shock protein TRAP1** inhibitor, with antiproliferative activity. 6BrCaQ can be used in the synthesis of 6BrCaQ-TPP conjugates.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6BrCaQ-C10-TPP

Cat. No.: HY-144831

6BrCaQ-C10-TPP is a potent **mitochondrial heat shock protein TRAP1** inhibitor, with antiproliferative activity in various human cancer cells (IC_{50}=0.008-0.30 μM). 6BrCaQ-C10-TPP can also induces mitochondrial membrane disturbance.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alvespimycin

(17-DMAG; NSC 707545)

Cat. No.: HY-10389

Alvespimycin (17-DMAG) is a potent inhibitor of **Hsp90**, binding to Hsp90 with an EC_{50} of 62 ± 29 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Alvespimycin hydrochloride

(17-DMAG hydrochloride; KOS-1022; BMS 826476)

Cat. No.: HY-12024

Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of **Hsp90**, binding to Hsp90 with EC_{50} of 62±29 nM.



Purity: 98.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg, 200 mg

Aminohexylgeldanamycin
(AHGDM)

Cat. No.: HY-133571

Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent **HSP90** inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Aminohexylgeldanamycin hydrochloride
(AHGDM hydrochloride)

Cat. No.: HY-133571A

Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent **HSP90** inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMP-PCP

Cat. No.: HY-106723

AMP-PCP is an ATP analogue and can bind to **Hsp90** N-terminal domain with a K_d value of 3.8 μM. AMP-PCP binding favors the formation of the active homodimer of **Hsp90**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMP-PCP disodium

Cat. No.: HY-106723A

AMP-PCP disodium is an ATP analogue and can bind to **Hsp90** N-terminal domain with a K_d value of 3.8 μM. AMP-PCP disodium binding favors the formation of the active homodimer of **Hsp90**.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Apatorsen
(OGX-427)

Cat. No.: HY-145722A

Apatorsen is an antisense oligonuc leotide designed to bind to&nb sp;**Hsp27** mRNA, resulting in& nbsp;the inhibition of the produc tion of Hsp27 protein.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apatorsen sodium
(OGX-427 sodium)

Cat. No.: HY-145722

Apatorsen (sodium) is an antisense ;oligonucleotide designed to bind&n bsp;to **Hsp27** mRNA, resulting in the inhibition of the&nb sp;production of Hsp27 protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apoptozole
(Apoptosis Activator VII)

Cat. No.: HY-15098

Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of **Hsc70** and **Hsp70**, with K_ds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Arimoclomol
(BRX-220 free base)

Cat. No.: HY-106443

Arimoclomol (BRX-220 free base) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arimoclomol citrate
(BRX-220 citrate)

Cat. No.: HY-106443B

Arimoclomol citrate (BRX-220 citrate) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arimoclomol maleate
(BRX-220)

Cat. No.: HY-106443A

Arimoclomol maleate (BRX-220) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Azadiradione

Cat. No.: HY-N9615

Azadiradione is a bioactive limonoid found in Azadirachta indica. Azadiradione is a **HSF1** activator. Azadiradione has antimycobacterial, anti-nociceptive and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIIB021

(CNF2024)

Cat. No.: HY-10212

BIIB021 (CNF2024) is an orally active, fully synthetic inhibitor of **HSP90** with a K_i and an EC_{50} of 1.7 nM and 38 nM, respectively.



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Bimoclomol

Cat. No.: HY-U00398

Bimoclomol is a **heat shock protein (HSP)** coinducer, used for treatment of cardiovascular diseases.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Calenduloside E

Cat. No.: HY-N6850

Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has **anti-apoptotic** potent by targeting heat shock protein 90 (**Hsp90**).



Purity: 98.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CCT018159

Cat. No.: HY-110042

CCT018159, a 3,4-diaryl pyrazoleresorcinol, is a ATP-competitive **HSP90 ATPase** activity inhibitor with IC_{50}s of 3.2 and 6.6 μM for human Hsp90β and yeast Hsp90, respectively. CCT018159 caused cell cytostasis associated with a G1 arrest and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCT251236

Cat. No.: HY-101026

CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC_{50} of 19 nM for inhibition of HSF1-mediated **HSP72** induction.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Cemdomespib

(KU-596)

Cat. No.: HY-145559

Cemdomespib (KU-596) is a highly bioavailable second-generation **Hsp90** modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chetomin

Cat. No.: HY-107553

Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (**Hsp90/HIF1α**) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Col003

Cat. No.: HY-124817

Col003 is a selective and potent inhibitor of **Hsp47** and competitively binds to the collagen binding site on Hsp47 (IC_{50}=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Conglobatin

(FW-04-806)

Cat. No.: HY-119906

Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active **Hsp90** inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Cucurbitacin D

Cat. No.: HY-N1986

Cucurbitacin D is an active component in Cucurbita texana, disrupts interactions between **Hsp90** and two co-chaperones, Cdc37 and p23. Cucurbitacin D prevents Hsp90 client (Her2, Raf, Cdk6, pAkt) maturation without induction of the heat shock response. Anti-cancer activity.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

DDO-5936

Cat. No.: HY-139301

DDO-5936 is a potent and specific **Hsp90-Cdc37 PPI** inhibitor. DDO-5936 can be used for the research of colorectal cancer.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Debio 0932

(CUDC-305)

Cat. No.: HY-13469

Debio 0932 (CUDC-305) is an orally active **HSP90** inhibitor, with IC_{50}s of 100 and 103 nM for HSP90α and HSP90β, respectively.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dihydroberberine

Cat. No.: HY-N1934

Dihydroberberine inhibits **human ether-a-go-go-related gene (hERG)** channels and remarkably reduces **heat shock protein 90 (Hsp90)** expression and its interaction with hERG.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

DTHIB

Cat. No.: HY-138280

DTHIB is a direct and selective **heat shock factor 1 (HSF1)** inhibitor with a K_d of 160 nM for **DTHIB binding to the HSF1 DNA binding domain (DBD)**. DTHIB inhibits **HSF1** cancer gene signature (HSF1 CaSig) and selectively stimulates degradation of nuclear **HSF1**.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EC144

Cat. No.: HY-13479

EC144 is a potent and selective inhibitor of heat shock protein 90 (**Hsp90**) with an IC_{50} of 1.1 nM. EC144 inhibits tumor growth and causes partial tumor regressions. EC144 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethoxyquin

Cat. No.: HY-B1425

Ethoxyquin is an antioxidant which has been used in animal feed for many years and also an inhibitor of **heat shock protein 90** (**Hsp90**).



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Eupalinolide A

Cat. No.: HY-N0754

Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of **HSF1** by inhibiting the interaction between HSF1 and HSP90.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Falcarinol

(Panaxynol; Carotatoxin)

Cat. No.: HY-N1455

Falcarinol (Panaxynol) is a natural, orally active **Hsp90** inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces **apoptosis**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Feretoside

Cat. No.: HY-N6249

Feretoside, a phenolic compound extracted from the barks of E. ulmoides, is a **HSP inducer** which act as cytoprotective agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Gamitrinib TPP

Cat. No.: HY-102007

Gamitrinib TPP is a **Gamitrinib (GA) mitochondrial matrix** inhibitor. Gamitrinib TPP is a mitochondrial targeted **HSP90** inhibitor with anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gamitrinib TPP hexafluorophosphate

Cat. No.: HY-102007A

Gamitrinib TPP hexafluorophosphate is a **Gamitrinib (GA) mitochondrial matrix** inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted **HSP90** inhibitor with anti-cancer activity.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Ganetespib

(STA-9090)

Cat. No.: HY-15205

Ganetespib (STA-9090) is a heat shock protein 90 (**HSP90**) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Gedunin

Cat. No.: HY-107577

Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent **Hsp90** inhibitor and induces the degradation of Hsp90-dependent client proteins.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Geldanamycin

Cat. No.: HY-15230

Geldanamycin is a **Hsp90** inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus **H5N1** activities.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Geldanamycin-FITC

Cat. No.: HY-133705

Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GRP78-IN-1

Cat. No.: HY-145857

GRP78-IN-1 exhibits several interactions with **GRP78** residues with binding energy of -8.07 kcal/mol. GRP78-IN-1 shows the potent cytotoxic, anti-proliferative in cancer cells. GRP78-IN-1 exhibits promising **apoptosis** in breast cancer cells and wound healing properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Grp94 Inhibitor-1

Cat. No.: HY-112910

Grp94 Inhibitor-1 is a potent, selective **Grp94** inhibitor with an IC_{50} value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HA15

Cat. No.: HY-100437

HA15 is a potent and specific inhibitor of ER chaperone **BiP/GRP78/HSPA5**, inhibits the ATPase activity of BiP, with anti-cancerous activity.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HA15-Biotin

Cat. No.: HY-139009

HA15-Biotin is a chemical probe that consists of HA15 and biotin attached on the amide part of HA15. HA15-Biotin exhibits similar levels of activity to HA15. HA15-Biotin can be used for proteomic analysis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hexadecanoate-13C16 potassium

Cat. No.: HY-W134007S1

Hexadecanoate-13C16 potassium is the 13C-labeled Hexadecanoate sodium. Hexadecanoate-13C16 potassium can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HM03

Cat. No.: HY-125974

HM03 is a potent and selective **HSPA5** (Heat shock 70kDa protein 5, also known as Bip, Grp78) inhibitor. HM03 has anticancer activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HM03 trihydrochloride

Cat. No.: HY-125974A

HM03 trihydrochloride is a potent and selective **HSPA5** (Heat shock 70kDa protein 5, also known as Bip, Grp78) inhibitor. HM03 trihydrochloride has anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HS-131

Cat. No.: HY-122878

HS-131, a near infrared dye tethered **Hsp90** inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HS-27

Cat. No.: HY-130851

HS-27, a fluorescently-tethered **Hsp90** inhibitor, assays surface Hsp90 expression on intact tissue specimens.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HSF1A

Cat. No.: HY-103000

HSF1A is a cell-permeable activator of heat shock transcription factor 1 (**HSF1**). HSF1A also acts as a specific inhibitor of TRiC/CCT. Chaperonin TCP-1 ring complex (TRiC)/chaperonin containing TCP-1 (CCT) plays a pivotal role in toxin translocation and/or refolding.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

HSP27 inhibitor J2

(J2)

Cat. No.: HY-124653

HSP27 inhibitor J2 (J2) is a **HSP27** inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof.



Purity: 99.25%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

HSP70-IN-1

Cat. No.: HY-12622

HSP70-IN-1 is a heat shock protein (**HSP**) inhibitor; inhibits the growth of Kasumi-1 cells with an IC_{50} of 2.3 μM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HSP70-IN-3

Cat. No.: HY-143400

HSP70-IN-3 is a potent **HSP70** inhibitor (IC_{50}s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (**Hedgehog** signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hsp90-Cdc37-IN-1

Cat. No.: HY-111414

Hsp90-Cdc37-IN-1 is an **Hsp90-Cdc37** interaction disruptor that inhibit cell migration and reverse drug resistance, with an IC_{50} of 140 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hsp90-Cdc37-IN-3

Cat. No.: HY-144650

Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol–imidazole derivative with **anticancer** activity. Hsp90-Cdc37-IN-3 inhibits **Hsp90–Cdc37** by covalent-binding, and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HSP90-IN-9

Cat. No.: HY-145814

HSP90-IN-9 is a potent and selective **HSP90** inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icapamespib

(PU-HZ151)

Cat. No.: HY-137441

Icapamespib (PU-HZ151) is a potent **HSP90** inhibitor with an **EC_{50}** of 5nM. Icapamespib is able to cross blood-brain barrier.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JG-98

Cat. No.: HY-117282

JG-98, an allosteric **heat shock protein 70 (Hsp70)** inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

KNK437

(Heat Shock Protein Inhibitor I)

Cat. No.: HY-100110

KNK437 is a **HSP** inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Kongensin A

Cat. No.: HY-N3417

Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent **HSP90** inhibitor that blocks **RIP3**-dependent necroptosishas. Kongensin A is a potent **necroptosis** inhibitor and an **apoptosis** inducer.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRIBB11

Cat. No.: HY-100872

KRIBB11 is an inhibitor of **Heat shock factor 1 (HSF1)**, with **IC_{50}** of 1.2 μM.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KU-32

Cat. No.: HY-108248

KU-32 is a novel, novobiocin-based **Hsp90** inhibitor that can protect against neuronal cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KW-2478

Cat. No.: HY-13468

KW-2478 is an inhibitor of **Hsp90α**, with an **IC_{50}** of 3.8 nM, and has antitumor activity against various human hematological tumor cells.



Purity: 98.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Luminespib

(VER-52296; AUY922; NVP-AUY922)

Cat. No.: HY-10215

Luminespib (VER-52296) is a potent **HSP90** inhibitor with **IC_{50}**s of 7.8 and 21 nM for HSP90α and HSP90β, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 100 mg, 200 mg

Macbecin

(Macbecin I; NSC 330499) Cat. No.: HY-107578

Macbecin is a stable **HSP90** inhibitor by binding to the ATP-binding site with an IC_{50} of 2 μM and a K_d of 0.24 μM. Macbecin exhibits antitumor and cytocidal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MKT-077

(FJ-776) Cat. No.: HY-15096

MKT-077 is a rhodacyanine dye and also a heat shock protein 70 (**Hsp70**) inhibitor which exhibits significant antitumor activity.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML346

Cat. No.: HY-18669

ML346 is an activator of **Hsp70 expression** and **HSF-1 activity**, with an EC_{50} of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MPC-0767

Cat. No.: HY-115499

MPC-0767 is a potent, selective, and orally active **hsp90** inhibitor. MPC-0767 is an L-alanine ester prodrug of MPC-3100 with improved chemical stability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MPC-3100

Cat. No.: HY-13301

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of **Hsp90** with potential antineoplastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NCT-58

Cat. No.: HY-145102

NCT-58 is a potent inhibitor of C-terminal **HSP90**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NMS-E973

Cat. No.: HY-17547

NMS-E973 is a potent and selective inhibitor of **HSP90**. NMS-E973 binds to the ATP binding site of **Hsp90α** with a DC_{50} of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

NPX800

Cat. No.: HY-145927

NPX800 is a potent **heat shock factor 1 (HSF1)** inhibitor. NPX800 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-HSP990

(HSP-990) Cat. No.: HY-15190

NVP-HSP990 is a potent and selective **Hsp90** inhibitor, with IC_{50} values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.



Purity: 99.77%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Onalespib

(AT13387) Cat. No.: HY-14463

Onalespib (AT13387) is a long-acting second-generation **Hsp90** inhibitor with a K_d of 0.71 nM.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

p5 Ligand for Dnak and DnaJ

Cat. No.: HY-P1887

p5 Ligand for Dnak and DnaJ is a nonapeptide, which corresponds to the main binding site for the 23-residue part of the presequence of mitochondrial aspartate aminotransferase. p5 Ligand for Dnak and DnaJ is a high-affinity ligand for DnaK and DnaJ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paeoniflorin

(Peoniflorin)

Cat. No.: HY-N0293

Paeoniflorin (Peoniflorin), a **heat shock protein**-inducing compound and a pinane monoterpene glycoside with various bioactivities, such as anticancer effects, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, reducing blood viscosity...



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 25 mg, 100 mg, 200 mg

Palmitic acid

Cat. No.: HY-N0830

Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of **glucose-regulated protein 78 (GRP78)** and **CCAAT/enhancer binding protein homologous protein (CHOP)** in in mouse granulosa cells.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Palmitic acid-1,2,3,4-13C4

Cat. No.: HY-N0830S

Palmitic acid-1,2,3,4-13C4 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-1-13C

Cat. No.: HY-N0830S3

Palmitic acid-1-13C is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Palmitic acid-13C

Cat. No.: HY-N0830S9

Palmitic acid-13C is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-13C sodium

Cat. No.: HY-N0830BS

Palmitic acid-13C sodium is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-13C16

Cat. No.: HY-N0830S6

Palmitic acid-13C16 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-13C16 sodium

Cat. No.: HY-N0830BS1

Palmitic acid-13C16 sodium is the 13C-labeled Palmitic acid sodium. Palmitic acid sodium is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-13C2

Cat. No.: HY-N0830S10

Palmitic acid-13C2 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-15,15,16,16,16-d5

Cat. No.: HY-N0830S1

Palmitic acid-15,15,16,16,16-d5 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-9,10-d2

Cat. No.: HY-N0830S8

Palmitic acid-9,10-d2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d1

Cat. No.: HY-N0830S18

Palmitic acid-d1 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d17

Cat. No.: HY-N0830S14

Palmitic acid-d17 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2

Cat. No.: HY-N0830S4

Palmitic acid-d2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2-1

Cat. No.: HY-N0830S11

Palmitic acid-d2-1 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2-2

Cat. No.: HY-N0830S15

Palmitic acid-d2-2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2-3

Cat. No.: HY-N0830S16

Palmitic acid-d2-3 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2-4

Cat. No.: HY-N0830S17

Palmitic acid-d2-4 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d2-5

Cat. No.: HY-N0830S19

Palmitic acid-d2-5 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d3

Cat. No.: HY-N0830S5

Palmitic acid-d3 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Palmitic acid-d31

Cat. No.: HY-N0830S2

Palmitic acid-d31 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Palmitic acid-d4

Cat. No.: HY-N0830S7

Palmitic acid-d4 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d4-1

Cat. No.: HY-N0830S12

Palmitic acid-d4-1 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d4-2

Cat. No.: HY-N0830S13

Palmitic acid-d4-2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d5

Cat. No.: HY-N0830S21

Palmitic acid-d5 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid-d9

Cat. No.: HY-N0830S20

Palmitic acid-d9 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pifithrin-μ

(PFTμ; 2-Phenylethynesulfonamide)

Cat. No.: HY-10940

Pifithrin-μ is an inhibitor of **p53** and **HSP70**, with antitumor and neuroprotective activity.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Pimitespib

(TAS-116)

Cat. No.: HY-15785

Pimitespib (TAS-116) is an oral bioavailable, ATP-competitive, highly specific **HSP90α/HSP90β** inhibitor (K_is of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94. Pimitespib demonstrates less ocular toxicity.



Purity: 99.31%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PROTAC HSP90 degrader BP3

Cat. No.: HY-115997

PROTAC HSP90 degrader BP3 is a potent and selective degradation of **HSP90** in a **CRBN**-dependent fashion. PROTAC HSP90 degrader BP3 has a certain certain degradation effect on **HSP90** protein in MCF-7 cells (DC_{50}=0.99 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Radicicol

(Monorden)

Cat. No.: HY-N6769

Radicicol is an inhibitor of **Hsp90** with an IC_{50} value of 1 μM. Radicicol binds to the ATPase domain of Hsp90 and prevents maturation of Hsp90 clients, leading to proteasomal degradation.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Retaspimycin

Cat. No.: HY-15263

Retaspimycin is a potent inhibitor of **Hsp90**, with EC_{50}s of 119 nM for both Hsp90 and Grp9.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Retaspimycin Hydrochloride

(IPI-504)

Cat. No.: HY-10210

Retaspimycin Hydrochloride is a potent inhibitor of **Hsp90** with EC_{50}s of 119 nM for both Hsp90 and Grp9.



Purity: 98.35%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rocaglamide

(Roc-A)

Cat. No.: HY-19356

Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of **NF-κB** activation in T-cells.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Shepherdin (79-87)

Cat. No.: HY-P1750

Shepherdin (79-87) is amino acids 79 to 87 fragment of Shepherdin. Shepherdin is a peptidomimetic antagonist of the complex between Hsp90 and Survivin. Anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNX-0723

Cat. No.: HY-119046

SNX-0723 is a potent **Hsp90** Inhibitor with **anti-Plasmodium** activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC_{50} of 3.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tamoxifen

(ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Cat. No.: HY-13757A

Tamoxifen (ICI 47699) is an orally active, selective **estrogen receptor** modulator (**SERM**) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tamoxifen Citrate (ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate)

Cat. No.: HY-13757

Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (**SERM**) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tamoxifen-d5

(ICI 47699-d5; (Z)-Tamoxifen-d5; trans-Tamoxifen-d5)

Cat. No.: HY-13757AS

Tamoxifen-d5 (ICI 47699-d5) is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (**SERM**). Tamoxifen is a potent **Hsp90** activator and enhances the Hsp90 molecular chaperone ATPase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tanespimycin

(17-AAG; NSC 330507; CP 127374)

Cat. No.: HY-10211

Tanespimycin (17-AAG) is a potent **HSP90** inhibitor with an IC_{50} of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity.



Purity: 99.07%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg, 200 mg

Teprenone
(Geranylgeranylacetone)

Cat. No.: HY-B0779

Teprenone is an anti-ulcer drug, and works as an inducer of heat shock proteins (**HSPs**).



Purity: 99.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

TRC051384

Cat. No.: HY-101712

TRC051384 is a heat shock protein 70 (**HSP70**) inducer.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

VER-155008

Cat. No.: HY-10941

VER-155008 is an inhibitor of **Hsp70**, with IC_{50}s of 0.5 μM, 2.6 μM, and 2.6 μM for **Hsp70**, Hsc70 and Grp7, respectively, and with a K_d of 0.3 μM for **Hsp70**.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VER-49009
(CCT 129397)

Cat. No.: HY-15986

VER-49009 is a **Hsp90** inhibitor, with an IC_{50} of 25 nM and a K_d of 78 nM.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

VER-50589

Cat. No.: HY-15984

VER-50589 is a **Hsp90** inhibitor, with an IC_{50} of 21 nM and a K_d of 4.5 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

VER-82576
(NVP-BEP800)

Cat. No.: HY-10942

VER-82576 (NVP-BEP800) is a potent, orally available and selective **Hsp90** inhibitor, with an IC_{50} of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC_{50}s of 4.1 and 5.5 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL888

Cat. No.: HY-13313

XL888 is a heat shock protein-90 (**HSP90**) inhibitor, with an IC_{50} of 24 nM.



Purity: 99.62%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

YK5

Cat. No.: HY-120909

YK5 is a potent and selective **Hsp70** inhibitor. YK5 selectively and tightly binds to the cytosolic Hsp70s in cancer cells. YK5 has biological activity partly by interfering with the formation of active oncogenic Hsp70/Hsp90/client protein complexes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YUM70

Cat. No.: HY-138364

YUM70 is a potent and selective inhibitor of **glucose-regulated protein 78 (GRP78)**, with an IC_{50} of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YZ129

Cat. No.: HY-114413

YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to **heat shock protein 90 (HSP90)** with an IC_{50} of 820 nM on NFAT nuclear translocation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg